• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias.

作者信息

Li Guo-Fu, Qiao Yu-Wei, Guan Ai-Jia, Yu Guo

机构信息

Guo-Fu Li, PhD, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China, Subei People's Hospital, Yangzhou, China; Yu-Wei Qiao, BM, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China; Ai-Jia Guan, BM, First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China; and Guo Yu, PhD, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.

出版信息

J Clin Oncol. 2023 Mar 10;41(8):1629-1630. doi: 10.1200/JCO.22.02234. Epub 2023 Jan 6.

DOI:10.1200/JCO.22.02234
PMID:36608304
Abstract
摘要

相似文献

1
Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias.TROPiCS-02试验中无进展生存期数据的信息性删失：一种未被认识到的偏倚
J Clin Oncol. 2023 Mar 10;41(8):1629-1630. doi: 10.1200/JCO.22.02234. Epub 2023 Jan 6.
2
Informative censoring - a neglected cause of bias in oncology trials.信息删失——肿瘤学试验中一个被忽视的偏倚原因。
Nat Rev Clin Oncol. 2020 Jun;17(6):327-328. doi: 10.1038/s41571-020-0368-0.
3
Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.信息性删失对II期临床试验中无进展生存期的Kaplan-Meier估计值的影响。
J Clin Oncol. 2014 Sep 20;32(27):3068-74. doi: 10.1200/JCO.2014.55.6340.
4
Progression-free survival in oncological clinical studies: Assessment time bias and methods for its correction.肿瘤学临床研究中的无进展生存期：评估时间偏倚及其校正方法。
Pharm Stat. 2021 Jul;20(4):864-878. doi: 10.1002/pst.2115. Epub 2021 Mar 29.
5
Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer.探索早期删失和分析临床试验生存数据对晚期乳腺癌有效性和成本效益估计的影响：一个案例研究。
Med Decis Making. 2018 Oct;38(7):789-796. doi: 10.1177/0272989X18790966. Epub 2018 Aug 20.
6
The role of censoring on progression free survival: oncologist discretion advised.删失对无进展生存期的作用：建议肿瘤学家酌情处理。
Eur J Cancer. 2015 Nov;51(16):2269-71. doi: 10.1016/j.ejca.2015.07.005. Epub 2015 Aug 7.
7
Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring.辅助免疫疗法在高危肌肉浸润性膀胱癌患者中的应用：信息性删失的潜在影响。
Cancer. 2022 Aug 1;128(15):2892-2897. doi: 10.1002/cncr.34255. Epub 2022 May 12.
8
Evaluating and adjusting for premature censoring of progression-free survival.评估无进展生存期的提前截尾并进行调整。
J Biopharm Stat. 2013;23(5):1091-105. doi: 10.1080/10543406.2013.813526.
9
The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustration.反对在癌症临床试验中对无进展生存期进行 censoring 的案例——以大流行封锁为例。
BMC Med Res Methodol. 2022 Oct 5;22(1):260. doi: 10.1186/s12874-022-01731-5.
10
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?III期临床试验中无进展生存期的盲态独立中央审查：重要的设计要素还是不必要的费用？
J Clin Oncol. 2008 Aug 1;26(22):3791-6. doi: 10.1200/JCO.2008.16.1711.

引用本文的文献

1
The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer.安罗替尼联合化疗对激素受体阳性转移性乳腺癌中细胞周期蛋白依赖性激酶4/6抑制剂进展后的影响。
Breast J. 2024 Aug 2;2024:5396107. doi: 10.1155/2024/5396107. eCollection 2024.
2
Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail.戈沙妥珠单抗治疗转移性乳腺癌的总生存获益：一项随机对照试验的事后交互分析
Clin Drug Investig. 2024 Jun;44(6):455-457. doi: 10.1007/s40261-024-01367-x. Epub 2024 Jun 5.
3
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
在激素受体阳性/HER2 阴性转移性乳腺癌中，一线化疗后使用 CDK4/6 抑制剂瑞博西林进行抗激素维持治疗：一项 II 期试验（AMICA）。
Breast. 2023 Dec;72:103575. doi: 10.1016/j.breast.2023.08.007. Epub 2023 Sep 1.